BRCA1 and neoplasm: Cells carrying intact Brca1 (Brca1+/+) showed no sensitivity to PDS or olaparib, while cells established from a Brca1−/− tumor were sensitive to both drugs, as determined in viability and clonogenic assays (Figures 7A, 7B, S7A, and S7B).